Pharmacological and Electroceutical Targeting of the Cholinergic Anti-Inflammatory Pathway in Autoimmune Diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms, preclinical studies, and clinical trials without systematic methodology
PubMed 37631004 · doi:10.3390/ph16081089
What was done
This narrative review synthesized preclinical and clinical evidence on the vagus nerve-mediated cholinergic anti-inflammatory pathway, focusing on pharmacological agents and bioelectronic nerve electrostimulation for modulating immune responses in autoimmune and inflammatory diseases.
What was found
The abstract reports no numerical data, effect sizes, or statistical metrics. It qualitatively notes that targeting this pathway via pharmacology or nerve electrostimulation was reported to reduce chronic inflammation in conditions such as rheumatoid arthritis and diabetes.
Why it matters
Modulating neuro-immune communication via electroceuticals or cholinergic drugs provides an alternative therapeutic framework for autoimmune disorders marked by decreased vagal tone.
Limits
The abstract provides no primary data, sample sizes, or quantitative outcome measures. As a narrative review, it lacks systematic search methodology, risk-of-bias assessment, and quantitative synthesis.
Cited by
- supports Phosphatidylcholine from lecithin serves as a precursor for acetylcholine, which is utilized in vagal nerve transmission.